1. Home
  2. CGEM vs CRAI Comparison

CGEM vs CRAI Comparison

Compare CGEM & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$17.59

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo CRA International Inc.

CRAI

CRA International Inc.

HOLD

Current Price

$172.74

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
CRAI
Founded
2016
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
CGEM
CRAI
Price
$17.59
$172.74
Analyst Decision
Strong Buy
Buy
Analyst Count
8
1
Target Price
$30.13
$245.00
AVG Volume (30 Days)
522.7K
128.4K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
1.48%
EPS Growth
N/A
20.77
EPS
N/A
8.14
Revenue
N/A
$751,583,000.00
Revenue This Year
N/A
$7.82
Revenue Next Year
$5.20
$5.14
P/E Ratio
N/A
$21.68
Revenue Growth
N/A
9.33
52 Week Low
$5.68
$132.17
52 Week High
$19.43
$227.29

Technical Indicators

Market Signals
Indicator
CGEM
CRAI
Relative Strength Index (RSI) 56.33 57.76
Support Level $17.19 $172.05
Resistance Level $19.10 $179.62
Average True Range (ATR) 0.89 8.37
MACD -0.05 -0.50
Stochastic Oscillator 81.78 59.49

Price Performance

Historical Comparison
CGEM
CRAI

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

Share on Social Networks: